A negative PSMA PET scan isn’t always a clean bill of health. Sometimes the cancer is just too quiet, too small, or too faint to show up. But it’s there. Rising PSA levels scream that something is wrong, yet the initial scan comes back blank. This disconnect leaves patients and doctors guessing.
New research changes that dynamic. It shows that a second PSMA PET scan catches the disease in 56 percent of these tricky cases. For nearly half of those men, finding that hidden cancer completely altered their treatment path. The findings hit The Journal of Nuclear Medicine in July, offering a clearer roadmap for when the first test fails to reveal the truth.
Understanding Biochemical Recurrence
Prostate cancer loves to return quietly. After surgery or radiation, there might be no symptoms. No lumps to feel, no pain. Just a creeping number on a lab report: the Prostate-Specific Antigen (PSA).
This is called biochemical recurrence. The cells are alive somewhere in the body, leaking PSA into the blood, but the map is blank. Where are they? Local recurrence near the prostate bed? Local lymph nodes? Or scattered in distant organs? Each scenario demands a different strike.
PSMA PET imaging helps bridge this gap. A radioactive tracer binds to the PSMA protein found on prostate cancer cells. It lights up areas of accumulation. It’s sharper than conventional CT or MRI. But it isn’t perfect. About 30 percent men with suspected recurrence get a “negative” scan despite rising PSA. The disease might be microscopic. Or the cells might not express enough PSMA to stand out from the noise.
Ur Metser, a radiologist at the University of Toronto’s Princess Margaret Cancer Centre, knew this gap was costly.
“There is little information on the utility of repepeating a PSMA PET after an initial nege scan.”
He and his team wanted to know: is waiting and rescanning worth it?
Who Should Get a Second Scan?
The study looked at 210 patients in the Ontario registry. These weren’t random picks. These were men whose first PSMA scan missed the mark, so they got scanned again later.
The results were stark. 56 percent of patients had detectable cancer on that second test.
But not everyone benefited equally. The data points to two specific markers that make a second scan highly likely to yield a hit:
- Higher absolute PSA levels.
- A rapid PSA doubling time of less than 12 monthsA fast-rising PSA suggests the disease is active and aggressive. It grows. And as it grows, it eventually becomes big enough—or noisy enough—to catch the eye of the tracer.
Changing the Treatment Game
Finding the cancer isn’t just about confirmation. It’s about action. In this study, the second scan changed management plans in nearly 5 percent of cases.
This matters most for men with oligometastatic disease fewer than five positive sites). Why? Because limited disease is often targetable. Doctors might consider radiation or surgery to remove specific tumors, rather than defaulting immediately to systemic therapies that hit the whole body.
The scan doesn’t pick the treatment. It draws the map. With a clear view of where the enemy is hiding, the choice between active surveillance, local ablation, or hormone therapy becomes a decision, not a gamble.
Metser sees this as a pivot point. “Understanding the extent of Disease in patients who have initial neative PSMA PET scans provides valuable information.”
So, if your PSA is climbing but your scan is blank, don’t assume you’re clear. It might just be early. Or subtle. Or waiting for a closer look. A second opinion from the imager could be the difference between watching and treating.
The clock is ticking on that doubling time.
